Back3D Medicines Overview
3D Medicines Inc.

3D Medicines Return on Equity

3D Medicines (1244.HK) has a ROE of -65.16%, below the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

-65.16%

Return on Equity

-65.16%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

3D Medicines (1244.HK) FAQ

3D Medicines (1244.HK) currently reports a ROE of -65.16%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore 3D Medicines's ROE history and peer comparisons.

3D Medicines's ROE of -65.16% is lower than the Healthcare sector average of 13.1%. That is roughly 597.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but 3D Medicines's current -65.16% should be judged against Healthcare norms (sector average: 13.1%) and against 1244.HK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -65.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for 3D Medicines, and consider following 1244.HK for alerts when major investors trade the stock.

3D Medicines is classified in the Healthcare sector. On ROE, it currently shows -65.16% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 1244.HK with unrelated industries.